Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
Rhea-AI Summary
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported EREFS endoscopic data from the Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis on May 5, 2026. The data show an association between the number of injections and EREFS improvement, with a 20-injection protocol producing the largest mean EREFS reduction.
Among 7 patients with baseline EREFS >2 who received 20 injections, mean EREFS fell by 65% (3.6 points) at week 12; highest-dose cohorts (8b and 9, combined n=4) showed near-complete EREFS improvement.
Positive
- Mean EREFS reduction 65% (3.6 points) at week 12 in 20-injection patients (n=7)
- 83% of participants (25 of 30) had baseline EREFS >2, indicating active disease in most enrollees
- Near-complete EREFS improvement reported in highest-dose cohorts 8b and 9 (combined n=4)
- Data support selection of a 20-injection pattern for broader esophageal coverage in Phase 2b
Negative
- Small sample sizes in reported subsets (20-injection group n=7; highest-dose combined n=4)
- EREFS responder data reported mainly at week 12; longer-term durability not yet shown for all cohorts
- Findings are from a Phase 1b/2a cohort and are not conclusive evidence of clinical benefit
News Market Reaction – EPRX
On the day this news was published, EPRX declined 2.02%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While EPRX is down 5.96%, peers show mixed moves: TRDA up 9.65%, TLSA up 5.3%, SLS up 2.24%, and HRTX down 5.43%. Momentum scanning only flagged VOR down 2.72%, suggesting today’s move is stock-specific rather than a coordinated biotech sector shift.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Conference presentation | Positive | +2.1% | Announcement of multiple EP-104GI abstracts and investor event at DDW. |
| Apr 21 | Clinical data update | Positive | -2.5% | Nine-month tissue health and symptom data from highest-dose RESOLVE cohort. |
| Apr 13 | Investor conferences | Positive | +4.7% | Participation in two April investor conferences with webcast presentation. |
| Mar 17 | Clinical data update | Positive | +2.6% | Six-month symptom data from highest-dose RESOLVE cohort and pooled remission rates. |
| Mar 12 | Earnings and financing | Positive | -1.9% | Q4 2025 results, cash balance, and public offering proceeds extending funding runway. |
Recent news has produced mixed reactions, with several positive clinical and corporate updates met by both gains and modest pullbacks.
Over the last few months, Eupraxia has repeatedly highlighted progress in its EP‑104GI program for EoE, including six‑ and nine‑month data from the Phase 1b/2a RESOLVE trial and upcoming and actual presentations at Digestive Disease Week. It also reported Q4 2025 financials and a capital raise that extended funding into the second half of 2028. Today’s detailed EREFS data build directly on those earlier symptom, tissue health, and durability findings.
Market Pulse Summary
This announcement adds quantitative EREFS evidence that a 20‑injection EP‑104GI protocol in EoE patients produced larger and more consistent endoscopic improvements, reinforcing prior symptom and tissue health data from RESOLVE. Investors may track how these findings inform the ongoing placebo‑controlled Phase 2b design, along with upcoming conference presentations and regulatory filings, while monitoring safety, durability of response at week 36, and future readout timing.
Key Terms
eosinophilic esophagitis endoscopic reference score medical
eoe medical
phase 1b/2a medical
phase 2b medical
placebo-controlled medical
endoscopy medical
AI-generated analysis. Not financial advice.
- EREFS is a standardized visual scoring system that gastroenterologists use when performing an endoscopy in EoE patients to assess the severity of inflammation and fibrosis in the esophagus
- EREFS data reported by Eupraxia demonstrated a relationship between the number of injections of EP-104GI and the overall improvements in the EREFS findings
- A consistent response in both the inflammatory and fibrotic sub scores of EREFS was demonstrated for patients who received 20 injections. This also represents the number of injections being studied in the placebo-controlled Phase 2b portion of the RESOLVE trial
VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago.
“The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”
Key highlights from the DDW presentation:
The EREFS measured in the study assesses the severity of five endoscopic features (domains) of EoE: edema, rings, exudates, furrows, and strictures at their most severe location. Individuals without EoE typically have EREFS at, or near, zero. Prior studies showed that patients with active EoE tend to present an EREFS of >2. Achieving an EREFS below 2 points has been validated as a response threshold in EoE1.
EREFS assessments from endoscopic examinations were conducted on all cohorts at baseline, week-12, and for patients in Cohorts 5-9 at week 36.
- In total, 25 of 30 (
83% ) of participants enrolled presented with an EREFS >2 at baseline. - For patients with baseline scores >2, the proportion of responders (defined as patients achieving EREFS of ≤2) at week 12 increased with the number of injections given.
- Of the 7 patients who had EREFS of >2 at baseline and 20 injections (resulting in near full coverage of the esophagus):
- The mean reduction in EREFS was
65% (3.6 points) from baseline at week 12 (n=7). - EREFS improvement was near complete in the highest-dose cohorts (8b and 9, 20x6mg and 20x8mg, combined n=4).
- The mean reduction in EREFS was
- EoEHSS inflammatory and fibrosis sub scores also indicate that higher dose cohorts overall suggest potentially greater improvement in either inflammatory or fibrotic features.
- Together, these results support the selection of an injection pattern of 20 injections for higher esophageal surface coverage.
A summary of the above results are posted in the Scientific Publications section of the Eupraxia Pharmaceuticals website and can be found here.
About the RESOLVE Trial
The Phase 1b/2a part of the RESOLVE trial is a multicenter, open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and efficacy of EP-104GI in adults with histologically confirmed active EoE. The treatment is administered as a single dose via 4 to 20 esophageal wall injections, with dose escalations modifying either the dose per site and/or the number of sites. Participants were followed for up to 24 weeks in Cohorts 1-4 (4x1mg, 8x1mg, 8x2.5mg and 12x2.5mg) or 52 weeks in Cohorts 5-9 (12x4mg, 16x4mg, 20x4mg, 20x6mg and 20x8mg). Eupraxia plans to disclose additional data from the open-label Phase 1b/2a part of the RESOLVE trial in the coming months.
The Phase 2b part of the RESOLVE trial, a randomized placebo-controlled study of EP-104GI, is currently recruiting both the 120mg (20x6mg) and 160mg (20x8mg) doses. The top-line data from the Phase 2b part of the RESOLVE trial is expected in Q4 2026.
Notes
1 Cotton et al. (2022) Endoscopy. 54(7):635-643
About Eosinophilic Esophagitis (EoE)
EoE is an inflammatory-mediated disease in which white blood cells migrate into and become trapped in the esophagus, creating pain and difficulty with swallowing food. According to market research from Clearview Healthcare Partners, EoE affects more than 450,000 people in the United States and has been identified by the American Gastroenterological Association as rapidly increasing in both incidence and prevalence. Impacts from both symptoms and interventions frequently lead to mental health issues, compounding the disease burden of EoE for both the healthcare system and the individual.
About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's Diffusphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.
Eupraxia's EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.
Notice Regarding Forward-looking Statements and Information
This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “is expected”, “expects”, “suggests”, “indicates”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes”, “potential” or variations (including negative and grammatical variations) of such words and phrases, or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the interpretation of clinical data from the RESOLVE trial, including 36-week data relating to tissue health and symptom response, as well as data presented at DDW; the Company’s expected timing of reporting additional data from the RESOLVE trial, including the Phase 2b portion thereof; the Company's product candidates, including their expected benefits with respect to safety, tolerability, efficacy and duration of effect and their potential use in therapeutic areas beyond pain and inflammatory gastrointestinal disease; the expectations regarding the advancement of the Company’s product candidates through clinical development; the results of clinical trials of the Company's product candidates, the potential for the Company’s technology to impact the drug delivery process; the potential market opportunity for the Company’s product candidates; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the possibility that the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the possibility that the Company's technology may not be successful for its intended use; the fact that the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the possibility that the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the possibility that the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the possibility that the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the fact that the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company’s active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the fact that the Company relies on external contract research organizations to provide clinical and non-clinical research services; the possibility that the Company may not be able to successfully execute its business strategy; the fact that the Company will require additional financing, which may not be available; the fact that any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.
For investor and media inquiries, please contact:
James Meikle, Eupraxia Pharmaceuticals Inc.
236-330-7084
jmeikle@eupraxiapharma.com
or
Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617-283-2856
kgardner@lifesciadvisors.com
SOURCE Eupraxia Pharmaceuticals Inc.
